Cardiac Allograft Vasculopathy
Cross-source consensus on Cardiac Allograft Vasculopathy from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Risks & contraindications
Highlighted claims
- Cardiac allograft vasculopathy is the dominant cause of death in paediatric heart transplant recipients more than three years after transplant. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- CAV develops through endothelial dysfunction and chronic inflammation that lead to donor coronary artery intimal thickening. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Established CAV is difficult to treat because current risk-factor management and immunosuppression do not reverse lesions. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Re-transplantation is described as the only definitive therapy for CAV, but it is not always feasible. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)